NewBiologix Expands to the U.S., Strengthening Gene and Cell Therapy Production

Published: 12 Dec 2024

Author: Precedence Research

Share :

A subsidiary of a Swiss biotechnology "new biologicals" company has officially launched its viral vector services for gene and cell therapy here in the United States. Very soon, the company will engage with American clients in real-time collaboration through various challenges related to viral vector production and genomic analysis. David Kelly has been appointed Business Development Manager, and he will lead the entity office in the US. This Xcell™ Portfolio comes with state-of-the-art tools such as Eng-HEK293 cell line, rAAV production, and genomic analysis, which make it possible to streamline the production of rAAVs associated with recombinant adeno for therapies, safer and more efficient for patients. To Dr. Igor Fisch, Chief Executive Officer of NewBiologix, this is indeed a historic moment toward the company's goals because here the Swiss precision is also matched with the commercial opportunities in the US market toward the mission of addressing the production bottleneck.

Expanding Presence in U.S. Biotech Markets

NewBiologix opened a new hub in the US to offer real-time support and collaboration to biotechs. David Kelly, who just joined the newly opened hub as Business Development Manager, has been in the gene and cell therapy field for over ten years, dedicating close to a decade of his career to stem cell manufacture and commercial development projects. Kelly will facilitate the sales and licensing opportunities across the US and Canada. He is very enthusiastic about joining NewBiologix, an innovative company reconfiguring the robustness associated with gene therapy production. He looks forward to developing collaborations and accelerating its impact in a highly dynamic market.

Introduction of the Xcell Portfolio

The offering of Xcell™ Portfolio from NewBiologix will provide state-of-the-art technologies in the "production and analysis of rAAV." The arsenal is made up of proprietary HEK293 cell lines, advanced manufacturing tools, genomic analytics, and a whole lot more, including Xcell™ Eng-HEK293 Cell Line, the seamless system for rAAV production and characterization, Xcell™ Genomic Analytical Platform - also known for deep genomic insights. It brings research to commercialization to maximize the reliability of the products, reduce storage costs, and enhance gene therapy safety.

Swiss Precision Meets U.S. Innovation

NewBiologix, a new biotechnology company based in Switzerland, has entered the United States market to open its doors to further improvements with Swiss precision and engineering. The company recently appointed David Kelly to the team, signifying the commitment to strengthening collaboration within the US biopharma ecosystem. NewBiologix aims to tackle key challenges of gene and cell therapy via more advanced rAAV production, broad-ranging analytics, and tailored solutions for improving viral vector yields, therapy safety and efficacy, and satisfying the specific needs of biopharma partners.

Implications for U.S. Healthcare 

NewBiologix is broadening its U.S. outreach for further advancement of gene therapy specific to rare diseases and oncology. By permitting even speedier development, the Xcell™ Portfolio will add to healthcare innovation through faster development of gene therapies. This also strengthens partnerships with some leading biotech firms and also creates jobs in the field of gene and cell therapy. The world demands more of those therapies, so the U.S. expansion and its engineered solutions in Switzerland would benefit NewBiologix as a partner t

o further drive such innovative healthcare solutions. The goal of the company is also to have safe as well as effective treatments available to patients all around the globe.